title: WIN 63480, a hydrophilic TCP-site ligand, has reduced agonist-independent NMDA ion channel access compared to MK-801 and phencyclidine.
abstract: NMDA channel blockers are potentially advantageous therapeutic agents for the treatment of ischemia and head trauma, which greatly elevate extracellular glutamate, because they should most effectively inhibit high levels of receptor activation. A novel high affinity TCP site ligand, WIN 63480, does not produce MK-801- or PCP-like behavioral activation at anti-ischemic doses. While WIN 63480, MK-801 and PCP were all observed to be effective blockers of open NMDA channels, WIN 63480 had much less access to closed NMDA channels. This difference may be due to the fact that WIN 63480 is hydrophilic (logD = -4.1) while MK-801 and PCP are lipophilic (logD = +1.8). In vivo, closed channel access may result in a non-competitive profile of antagonism for MK-801 and PCP compared to a more uncompetitive profile for WIN 63480. Release of glutamate, and depolarization, are likely to produce a high level of NMDA receptor activation in ischemic areas compared to normal tissue. Consequently, at anti-ischemic doses, WIN 63480 may produce less inhibition of physiological NMDA-mediated processes in neural systems involved in behavioral regulation than MK-801 or PCP, leading to an improved side effect profile.
authors.affiliation: Department of Neuroscience, Sanofi Winthrop Inc., Collegeville, PA 19426-0900, USA.
authors.forename: B
authors.initials: B
authors.lastname: Ault
authors.forename: M S
authors.initials: MS
authors.lastname: Miller
authors.forename: M D
authors.initials: MD
authors.lastname: Kelly
authors.forename: L M
authors.initials: LM
authors.lastname: Hildebrand
authors.forename: W G
authors.initials: WG
authors.lastname: Earley
authors.forename: D
authors.initials: D
authors.lastname: Luttinger
authors.forename: J P
authors.initials: JP
authors.lastname: Mallamo
authors.forename: S J
authors.initials: SJ
authors.lastname: Ward
mesh_terms: D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000187:drug effects* / Q000378:metabolism; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D007736:Kynurenic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects; D051379:Mice; D010622:Phencyclidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D011807:Quinolizines / Q000494:pharmacology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D014162:Transfection; D014982:Xenopus laevis
chemical_list: D018691:Excitatory Amino Acid Antagonists; D011807:Quinolizines; D016194:Receptors, N-Methyl-D-Aspartate; C098914:Win 63480; D016291:Dizocilpine Maleate; C012058:tenocyclidine; D007736:Kynurenic Acid; D010622:Phencyclidine; C057013:7-chlorokynurenic acid